HEADER TRANSFERASE/TRANSFERASE INHIBITOR 13-APR-18 6D2I TITLE JAK2 PSEUDOKINASE V617F IN COMPLEX WITH AT9283 COMPND MOL_ID: 1; COMPND 2 MOLECULE: TYROSINE-PROTEIN KINASE; COMPND 3 CHAIN: A, B; COMPND 4 EC: 2.7.10.2; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: JAK2; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 8 EXPRESSION_SYSTEM_CELL_LINE: SF9; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID KEYWDS KINASE, PSEUDOKINASE DOMAIN, TRANSFERASE-TRANSFERASE INHIBITOR KEYWDS 2 COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR Q.LI,K.LI,M.J.ECK REVDAT 4 30-OCT-24 6D2I 1 REMARK REVDAT 3 04-OCT-23 6D2I 1 REMARK REVDAT 2 01-MAY-19 6D2I 1 JRNL REVDAT 1 20-MAR-19 6D2I 0 JRNL AUTH R.MCNALLY,Q.LI,K.LI,C.DEKKER,E.VANGREVELINGHE,M.JONES, JRNL AUTH 2 P.CHENE,R.MACHAUER,T.RADIMERSKI,M.J.ECK JRNL TITL DISCOVERY AND STRUCTURAL CHARACTERIZATION OF ATP-SITE JRNL TITL 2 LIGANDS FOR THE WILD-TYPE AND V617F MUTANT JAK2 PSEUDOKINASE JRNL TITL 3 DOMAIN. JRNL REF ACS CHEM. BIOL. V. 14 587 2019 JRNL REFN ESSN 1554-8937 JRNL PMID 30763067 JRNL DOI 10.1021/ACSCHEMBIO.8B00722 REMARK 2 REMARK 2 RESOLUTION. 3.19 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (1.13_2998: ???) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.19 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 42.26 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.340 REMARK 3 COMPLETENESS FOR RANGE (%) : 97.9 REMARK 3 NUMBER OF REFLECTIONS : 11238 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.272 REMARK 3 R VALUE (WORKING SET) : 0.271 REMARK 3 FREE R VALUE : 0.290 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.090 REMARK 3 FREE R VALUE TEST SET COUNT : 572 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 42.2681 - 5.0647 0.98 2766 162 0.2768 0.2997 REMARK 3 2 5.0647 - 4.0210 0.99 2694 133 0.2432 0.2900 REMARK 3 3 4.0210 - 3.5130 0.99 2643 152 0.2776 0.2612 REMARK 3 4 3.5130 - 3.1919 0.96 2563 125 0.3118 0.3086 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.280 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 29.900 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 22.27 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.002 4553 REMARK 3 ANGLE : 0.506 6158 REMARK 3 CHIRALITY : 0.039 670 REMARK 3 PLANARITY : 0.003 791 REMARK 3 DIHEDRAL : 15.015 2750 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6D2I COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 16-APR-18. REMARK 100 THE DEPOSITION ID IS D_1000233643. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 03-MAY-16 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 23-ID-D REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.984 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 11293 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.190 REMARK 200 RESOLUTION RANGE LOW (A) : 42.350 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.2 REMARK 200 DATA REDUNDANCY : 5.600 REMARK 200 R MERGE (I) : 0.13800 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 8.9000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 3.19 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.41 REMARK 200 COMPLETENESS FOR SHELL (%) : 93.7 REMARK 200 DATA REDUNDANCY IN SHELL : 5.60 REMARK 200 R MERGE FOR SHELL (I) : 0.71150 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.100 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 4L00 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 53.36 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.64 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1M TRIS PH 8, 0.1M MGACETATE AND 24% REMARK 280 W/V PEG4000, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 31.95250 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 56.55000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 45.56550 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 56.55000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 31.95250 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 45.56550 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 VAL B 536 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PHE A 537 76.22 -168.72 REMARK 500 ASN A 548 -98.91 -109.52 REMARK 500 GLN A 553 -168.23 -77.95 REMARK 500 HIS A 587 50.39 -110.05 REMARK 500 PHE A 617 50.30 -91.03 REMARK 500 CYS A 618 92.88 -56.68 REMARK 500 THR A 668 50.69 37.35 REMARK 500 HIS A 671 -70.56 -88.15 REMARK 500 ASN A 673 59.85 -145.67 REMARK 500 GLU A 779 -67.40 -98.22 REMARK 500 MET A 788 53.53 -100.24 REMARK 500 ASN B 548 -86.73 -106.97 REMARK 500 THR B 555 85.24 -68.64 REMARK 500 PHE B 617 50.85 -92.41 REMARK 500 CYS B 618 93.46 -58.89 REMARK 500 ASN B 641 50.41 -118.02 REMARK 500 ASN B 673 54.59 -145.84 REMARK 500 ASN B 729 34.10 -89.06 REMARK 500 ALA B 778 166.95 69.67 REMARK 500 MET B 788 49.83 -97.61 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 35R A 901 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 35R B 901 DBREF 6D2I A 536 808 UNP Q506Q0 Q506Q0_HUMAN 536 808 DBREF 6D2I B 536 808 UNP Q506Q0 Q506Q0_HUMAN 536 808 SEQADV 6D2I ALA A 659 UNP Q506Q0 TRP 659 ENGINEERED MUTATION SEQADV 6D2I ALA A 777 UNP Q506Q0 TRP 777 ENGINEERED MUTATION SEQADV 6D2I HIS A 794 UNP Q506Q0 PHE 794 ENGINEERED MUTATION SEQADV 6D2I ALA B 659 UNP Q506Q0 TRP 659 ENGINEERED MUTATION SEQADV 6D2I ALA B 777 UNP Q506Q0 TRP 777 ENGINEERED MUTATION SEQADV 6D2I HIS B 794 UNP Q506Q0 PHE 794 ENGINEERED MUTATION SEQRES 1 A 273 VAL PHE HIS LYS ILE ARG ASN GLU ASP LEU ILE PHE ASN SEQRES 2 A 273 GLU SER LEU GLY GLN GLY THR PHE THR LYS ILE PHE LYS SEQRES 3 A 273 GLY VAL ARG ARG GLU VAL GLY ASP TYR GLY GLN LEU HIS SEQRES 4 A 273 GLU THR GLU VAL LEU LEU LYS VAL LEU ASP LYS ALA HIS SEQRES 5 A 273 ARG ASN TYR SER GLU SER PHE PHE GLU ALA ALA SER MET SEQRES 6 A 273 MET SER LYS LEU SER HIS LYS HIS LEU VAL LEU ASN TYR SEQRES 7 A 273 GLY VAL CYS PHE CYS GLY ASP GLU ASN ILE LEU VAL GLN SEQRES 8 A 273 GLU PHE VAL LYS PHE GLY SER LEU ASP THR TYR LEU LYS SEQRES 9 A 273 LYS ASN LYS ASN CYS ILE ASN ILE LEU TRP LYS LEU GLU SEQRES 10 A 273 VAL ALA LYS GLN LEU ALA ALA ALA MET HIS PHE LEU GLU SEQRES 11 A 273 GLU ASN THR LEU ILE HIS GLY ASN VAL CYS ALA LYS ASN SEQRES 12 A 273 ILE LEU LEU ILE ARG GLU GLU ASP ARG LYS THR GLY ASN SEQRES 13 A 273 PRO PRO PHE ILE LYS LEU SER ASP PRO GLY ILE SER ILE SEQRES 14 A 273 THR VAL LEU PRO LYS ASP ILE LEU GLN GLU ARG ILE PRO SEQRES 15 A 273 TRP VAL PRO PRO GLU CYS ILE GLU ASN PRO LYS ASN LEU SEQRES 16 A 273 ASN LEU ALA THR ASP LYS TRP SER PHE GLY THR THR LEU SEQRES 17 A 273 TRP GLU ILE CYS SER GLY GLY ASP LYS PRO LEU SER ALA SEQRES 18 A 273 LEU ASP SER GLN ARG LYS LEU GLN PHE TYR GLU ASP ARG SEQRES 19 A 273 HIS GLN LEU PRO ALA PRO LYS ALA ALA GLU LEU ALA ASN SEQRES 20 A 273 LEU ILE ASN ASN CYS MET ASP TYR GLU PRO ASP HIS ARG SEQRES 21 A 273 PRO SER PHE ARG ALA ILE ILE ARG ASP LEU ASN SER LEU SEQRES 1 B 273 VAL PHE HIS LYS ILE ARG ASN GLU ASP LEU ILE PHE ASN SEQRES 2 B 273 GLU SER LEU GLY GLN GLY THR PHE THR LYS ILE PHE LYS SEQRES 3 B 273 GLY VAL ARG ARG GLU VAL GLY ASP TYR GLY GLN LEU HIS SEQRES 4 B 273 GLU THR GLU VAL LEU LEU LYS VAL LEU ASP LYS ALA HIS SEQRES 5 B 273 ARG ASN TYR SER GLU SER PHE PHE GLU ALA ALA SER MET SEQRES 6 B 273 MET SER LYS LEU SER HIS LYS HIS LEU VAL LEU ASN TYR SEQRES 7 B 273 GLY VAL CYS PHE CYS GLY ASP GLU ASN ILE LEU VAL GLN SEQRES 8 B 273 GLU PHE VAL LYS PHE GLY SER LEU ASP THR TYR LEU LYS SEQRES 9 B 273 LYS ASN LYS ASN CYS ILE ASN ILE LEU TRP LYS LEU GLU SEQRES 10 B 273 VAL ALA LYS GLN LEU ALA ALA ALA MET HIS PHE LEU GLU SEQRES 11 B 273 GLU ASN THR LEU ILE HIS GLY ASN VAL CYS ALA LYS ASN SEQRES 12 B 273 ILE LEU LEU ILE ARG GLU GLU ASP ARG LYS THR GLY ASN SEQRES 13 B 273 PRO PRO PHE ILE LYS LEU SER ASP PRO GLY ILE SER ILE SEQRES 14 B 273 THR VAL LEU PRO LYS ASP ILE LEU GLN GLU ARG ILE PRO SEQRES 15 B 273 TRP VAL PRO PRO GLU CYS ILE GLU ASN PRO LYS ASN LEU SEQRES 16 B 273 ASN LEU ALA THR ASP LYS TRP SER PHE GLY THR THR LEU SEQRES 17 B 273 TRP GLU ILE CYS SER GLY GLY ASP LYS PRO LEU SER ALA SEQRES 18 B 273 LEU ASP SER GLN ARG LYS LEU GLN PHE TYR GLU ASP ARG SEQRES 19 B 273 HIS GLN LEU PRO ALA PRO LYS ALA ALA GLU LEU ALA ASN SEQRES 20 B 273 LEU ILE ASN ASN CYS MET ASP TYR GLU PRO ASP HIS ARG SEQRES 21 B 273 PRO SER PHE ARG ALA ILE ILE ARG ASP LEU ASN SER LEU HET 35R A 901 28 HET 35R B 901 28 HETNAM 35R 1-CYCLOPROPYL-3-{3-[5-(MORPHOLIN-4-YLMETHYL)-1H- HETNAM 2 35R BENZIMIDAZOL-2-YL]-1H-PYRAZOL-4-YL}UREA FORMUL 3 35R 2(C19 H23 N7 O2) HELIX 1 AA1 ARG A 541 GLU A 543 5 3 HELIX 2 AA2 ASP A 569 GLY A 571 5 3 HELIX 3 AA3 LYS A 585 ASN A 589 5 5 HELIX 4 AA4 TYR A 590 SER A 602 1 13 HELIX 5 AA5 SER A 633 ASN A 641 1 9 HELIX 6 AA6 LYS A 642 ILE A 645 5 4 HELIX 7 AA7 ASN A 646 ASN A 667 1 22 HELIX 8 AA8 SER A 703 LEU A 707 5 5 HELIX 9 AA9 PRO A 708 ARG A 715 1 8 HELIX 10 AB1 PRO A 720 ASN A 726 1 7 HELIX 11 AB2 ASN A 731 GLY A 749 1 19 HELIX 12 AB3 ASP A 758 ASP A 768 1 11 HELIX 13 AB4 LEU A 780 MET A 788 1 9 HELIX 14 AB5 GLU A 791 ARG A 795 5 5 HELIX 15 AB6 SER A 797 SER A 807 1 11 HELIX 16 AB7 ARG B 541 GLU B 543 5 3 HELIX 17 AB8 HIS B 587 ASN B 589 5 3 HELIX 18 AB9 TYR B 590 LYS B 603 1 14 HELIX 19 AC1 SER B 633 ASN B 641 1 9 HELIX 20 AC2 LYS B 642 ILE B 645 5 4 HELIX 21 AC3 ASN B 646 ASN B 667 1 22 HELIX 22 AC4 SER B 703 LEU B 707 5 5 HELIX 23 AC5 PRO B 708 ARG B 715 1 8 HELIX 24 AC6 PRO B 720 ASN B 726 1 7 HELIX 25 AC7 ASN B 731 GLY B 749 1 19 HELIX 26 AC8 ASP B 758 ASP B 768 1 11 HELIX 27 AC9 LEU B 780 MET B 788 1 9 HELIX 28 AD1 GLU B 791 ARG B 795 5 5 HELIX 29 AD2 SER B 797 SER B 807 1 11 SHEET 1 AA1 5 LEU A 545 GLN A 553 0 SHEET 2 AA1 5 THR A 557 VAL A 567 -1 O LYS A 561 N GLU A 549 SHEET 3 AA1 5 LEU A 573 LEU A 583 -1 O HIS A 574 N GLU A 566 SHEET 4 AA1 5 ILE A 623 GLU A 627 -1 O GLN A 626 N LEU A 579 SHEET 5 AA1 5 ASN A 612 CYS A 616 -1 N CYS A 616 O ILE A 623 SHEET 1 AA2 2 ILE A 679 ARG A 683 0 SHEET 2 AA2 2 PHE A 694 LEU A 697 -1 O LYS A 696 N LEU A 680 SHEET 1 AA3 6 LYS B 539 ILE B 540 0 SHEET 2 AA3 6 ASN B 612 CYS B 616 1 O VAL B 615 N ILE B 540 SHEET 3 AA3 6 ILE B 623 GLU B 627 -1 O ILE B 623 N CYS B 616 SHEET 4 AA3 6 LEU B 573 LEU B 583 -1 N LYS B 581 O LEU B 624 SHEET 5 AA3 6 THR B 557 VAL B 567 -1 N GLY B 562 O VAL B 578 SHEET 6 AA3 6 LEU B 545 GLN B 553 -1 N GLU B 549 O LYS B 561 SHEET 1 AA4 2 ILE B 679 ARG B 683 0 SHEET 2 AA4 2 PHE B 694 LEU B 697 -1 O PHE B 694 N ARG B 683 SSBOND 1 CYS A 616 CYS A 618 1555 1555 2.04 SSBOND 2 CYS B 616 CYS B 618 1555 1555 2.04 CISPEP 1 ILE A 716 PRO A 717 0 5.73 CISPEP 2 ILE B 716 PRO B 717 0 5.47 SITE 1 AC1 12 LEU A 551 ILE A 559 LEU A 579 LYS A 581 SITE 2 AC1 12 GLU A 627 PHE A 628 VAL A 629 LYS A 630 SITE 3 AC1 12 PHE A 631 SER A 633 LEU A 680 SER A 698 SITE 1 AC2 12 ILE B 559 LEU B 579 LYS B 581 GLU B 627 SITE 2 AC2 12 VAL B 629 LYS B 630 PHE B 631 GLY B 632 SITE 3 AC2 12 SER B 633 LYS B 677 LEU B 680 SER B 698 CRYST1 63.905 91.131 113.100 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015648 0.000000 0.000000 0.00000 SCALE2 0.000000 0.010973 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008842 0.00000